primary liver cancer
Conditions
Interventions
A:DEB-TACE postoperative assisted hyperbaric oxygen therapy
B:Routine follow-up observation after DEB-TACE surgery
Sponsors
Air Force Medical University Xijing Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with primary hepatocellular carcinoma (HCC) clearly diagnosed by clinical, imaging examination and histopathology, with stage CNLC-IIb-IIIa and BCLC stage B-C; 2. Age between 18~80 years old, gender is not limited; 3. Those who do not have surgical resection or refuse surgical treatment, or who have recurred after surgery, and are suitable for DEB-TACE treatment after multidisciplinary discussion (no extrahepatic metastasis or portal vein main cancer thrombus (branch cancer thrombus is allowed)); 4. Preoperative liver function Child-Pugh grade A-B, normal coagulation function or mild to moderate abnormalities allowed interventional treatment; ECOG performance status score =6 months; 5. The patient has a clear consciousness and can better cooperate with treatment and follow-up; 6. Patients sign the informed consent form and voluntarily participate in this study.
Exclusion criteria
Exclusion criteria: 1. Combined with serious systemic diseases, such as severe cardiopulmonary abnormalities, moderate or above renal insufficiency, severe infection, and a history of obvious gastrointestinal bleeding; 2. Recent treatment of other forms of anti-tumor therapy (such as radiofrequency ablation, microwave ablation, chemotherapy, etc.), and the potential interference and confounding factors of these therapies cannot be ruled out; 3. Femoral or radial artery access puncture has obvious contraindications or previous puncture technique failure, which is not conducive to DEB-TACE (complete portal vein main occlusion); 4. Those with contraindications to hyperbaric oxygen therapy (such as severe alveolar bullae, uncontrolled hypertension (systolic blood pressure (SBP)>=160 mmHg or diastolic blood pressure (DBP)>=100 mmHg), otitis media, intracranial hypertension, pneumothorax, history of seizures, claustrophobia (severe psychological disorder), history of other respiratory infections, etc.); 5. Severe bleeding tendency or abnormal coagulation function, allergic constitution or allergy to treatment-related drugs and iodine contrast agents; 6. Pregnant or lactating women, patients with mental illness, and those who have not signed the informed consent form before enrollment;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate;Disease Control Rate (DCR, covering CR+PR+SD);Incidence of adverse reactions and changes in liver and kidney function (AE; QoL);Quality of life (Karnofsky functional status score) status; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease progression free survival (PFS);Overall survival rate OS; | — |
Countries
China
Contacts
Public ContactXu Jian
Air Force Medical University Xijing Hospital
Outcome results
None listed